) The Automated DNA Sequencing Facility was originally established as a Protein Sequencing Facility in 1974. Later, nucleic acid sequencing supplemented, and then replaced amino acid sequencing. Dr. Richard Hardy assumed direction of the Facility in 1993. Automated sequencing using an ABI Model 373 was set up in 1994. Model 377 sequencers were subsequently added, one in 1995, and another in 1997. The DNA Sequencing Facility provides Fox Chase investigators with computer-readable sequences of their DNA samples in a timely and cost effective manner, generating data more rapidly and of greater read-length compared to manual sequencing. Automated sequence analysis is used by investigators to verify DNA constructs, to identify mutations, and to determine the structure of newly cloned genes. Sequencing large genes (5-20 Kb) is much more tractable using automated sequence analysis, generating results in a few weeks, as compared to months using manual sequencing. The volume of usage of the Facility has increased strikingly over the past five years from 5,000 sequences in 1994 to over 17,000 in 1998. In addition to sequencing, analysis of DNA polymorphisms, important in genetic mapping studies, is also available in the Facility using """"""""GeneScan"""""""" software. Sequencing reactions are done during the day and run overnight. GeneScan runs are performed during the day on the Model 377XL instruments. The Facility is used by 45 peer-review funded investigators (represents 98 percent of the Facility usage) across 13 scientific Programs from all three Divisions. Equitable access to the Facility is assured by a faculty Oversight Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-40
Application #
6652203
Study Section
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
40
Fiscal Year
2002
Total Cost
$196,218
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298
Mishra, Om P; Popov, Anatoliy V; Pietrofesa, Ralph A et al. (2018) Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits myeloperoxidase activity in inflammatory cells. Biochim Biophys Acta Gen Subj 1862:1364-1375
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142

Showing the most recent 10 out of 1280 publications